# Avoro Ventures

> Avoro Ventures is a VC fund backing Biotechnology and Medical. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Oct 2025
- Lead investor: 14%
- Last updated: Aug 2026

Avoro Ventures is an investment firm that manages biopharma venture funds.

## Contacts

5 contacts available for Avoro Ventures. Shizune tracks 1 team members at Avoro Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/avoro-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 71% |
| Medical | 3 | 43% |
| Life Science | 3 | 43% |
| Biopharma | 1 | 14% |
| Health Care | 1 | 14% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 57% |
| Series C | 1 | 14% |
| Post-IPO Equity | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Denmark | 1 | 14% |
| United Kingdom | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Behzad Aghazadeh | Managing Partner | 3 | https://shizune.co/investors/profile/behzad-aghazadeh |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hemab | Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $157M | Series C | Oct 27, 2025 |  |
| Vicebio | Vicebio is committed to employing the Molecular Clamp Technology to create vaccines against next-generation respiratory viruses. Vicebio is a biopharmaceutical business that creates innovative vaccinations to prevent potentially fatal respiratory viral infections. | $100M | Series B | Sep 23, 2024 |  |
| Hemab | Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threateningcomplications. | $135M | Series B | Feb 21, 2023 |  |
| Vanqua Bio | Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases. Founded in 2019, the company's technology platform utilizes human genetics and patient-derived neuronal cells to identify, validate, and clinically translate novel disease pathways associated with lysosomaldysfunction or aberrant activation of the innate immune system. | $85M | Series B | Sep 14, 2021 |  |
| Vanqua Bio | Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases. Founded in 2019, the company's technology platform utilizes human genetics and patient-derived neuronal cells to identify, validate, and clinically translate novel disease pathways associated with lysosomaldysfunction or aberrant activation of the innate immune system. | $85M | Series B | Sep 14, 2021 |  |
| Whitehawk Therapeutics | Aadi Bioscience was founded by Dr. Neil Desai, is a clinical-stage biopharmaceutical company developing the potentially best-in-class mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases. | $155M | Post-IPO Equity | Aug 26, 2021 |  |
| Scribe Therapeutics | Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. Italso a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA. | $100M | Series B | Mar 31, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 9 deals together
- [Omega Funds](https://shizune.co/investors/profile/omega-funds) — VC Fund, 4 deals together
- [Access Biotechnology](https://shizune.co/investors/profile/access-biotechnology) — VC Fund, 3 deals together
- Avoro Capital Advisors — VC Fund, 3 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 3 deals together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Avoro Ventures invest in?

Avoro Ventures invests primarily in Biotechnology, Medical and Life Science startups, most often at Series B and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Avoro Ventures?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Avoro Ventures?

The team at Avoro Ventures includes Behzad Aghazadeh (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co